Genentech, a member of the Roche Group, has commenced construction of a new manufacturing site in Holly Springs in the US state of North Carolina.
The 65,000m² facility represents Genentech’s first manufacturing plant on the US East Coast.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will focus on producing medicines from the company’s metabolic portfolio, including next-generation treatments for obesity.
Genentech’s initial investment in the facility is estimated to exceed $700m. This investment is part of Roche’s $50bn commitment to enhance US manufacturing and research and development capacity.
The Holly Springs site will create 1,900 jobs.
Roche Group chief executive Thomas Schinecker stated: “I am proud to break ground on our new state-of-the-art manufacturing facility in North Carolina, which will support the production of our next-generation obesity treatments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This $700 million project is an integral part of our broader $50 billion commitment to further expand our already significant presence in the United States, building on our 120-year legacy of driving innovation and creating jobs across America.
“I am excited about the impact this facility will have on delivering life-changing medicines to patients in the US and around the world.”
Genentech chose Holly Springs, North Carolina, as its location due to its reputation as a centre for biopharmaceutical innovation. This decision is driven by the area’s skilled workforce, academic institution and its close proximity to other prominent life science companies.
The facility, designed for high-volume, efficient and sustainable production, will be operational by 2029. Situated on a 400,000m² site, it will incorporate automation and digital technologies and have capacity for future expansion.
